成人乙型肝炎免疫:接种针次数量重要吗?
结果显示,使用两剂疫苗可使每百万人中一年内获得血清保护者增加275,000人,且尽管HEPLISAV-B单价更高,其每获得一例血清保护者的平均成本低50-70美元(约15%)。
要点
- 两剂HBV疫苗较三剂疫苗使每百万人一年内血清保护者增加275,000人。
- HEPLISAV-B每剂成本高于ENGERIX-B,但每获得一例血清保护者成本低50-70美元(约15%)。
- 两剂疫苗提高完全接种人数,可能改善依从性和总体血清保护水平。
核心结论
- 使用两剂HBV疫苗较三剂疫苗可增加一年内完全血清保护的成人数量。
- 尽管HEPLISAV-B单价更高,其每获得一例血清保护者的平均预期成本显著低于ENGERIX-B。
研究设计与样本
- 按年龄分层(30-49岁 vs ≥50岁),使用已发表的HBV疫苗依从率及按接种剂次报告的血清保护率进行估计,并比较两种疫苗的免疫总预期成本。
主要发现
- 使用两剂而非三剂HBV疫苗,每百万人中一年内预期血清保护者增加275,000人,主要反映完全接种者预期增加290,000人。
- 两个年龄组结果相似。
- HEPLISAV-B每剂成本高于ENGERIX-B,但每获得一例血清保护者的估计平均成本低50-70美元(约15%)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At least one-half of adults beginning an immunization series with a three-dose hepatitis B virus (HBV) vaccine (ENGERIX-B, RECOMBIVAX-B) have been reported not to receive the third dose. Use of a two-dose vaccine may improve adherence and lead to greater overall levels of seroprotection. OBJECTIVE: To examine expected levels of adherence and overall seroprotection at one year among adults in routine clinical settings beginning an immunization series with either ENGERIX-B or the two-dose HBV vaccine, HEPLISAV-B. METHODS: Decision-analytic model comparing expected levels of adherence and overall seroprotection at one year among a hypothetical cohort of one million previously unvaccinated adults aged ≥ 30 years receiving first doses of either ENGERIX-B or HEPLISAV-B in a routine clinical setting. We stratified the population by age (30-49 years vs ≥ 50 years) to allow for possible differences in adherence and seroprotection. We estimated our model using published adherence rates for HBV vaccines, and reported seroprotection rates by number of doses administered. We also compared total expected costs of HBV immunization with each vaccine. RESULTS: Use of a two-dose rather than three-dose HBV vaccine would increase the expected number of adults seroprotected at one year by 275,000 per one million persons beginning immunization series, largely reflecting a gain of 290,000 in the expected number of persons fully vaccinated. Results were similar for the two age groups. While the cost per dose of HEPLISAV-B exceeds that of ENGERIX-B, its estimated mean cost per person seroprotected at one year is $50-$70 (∼15%) lower. CONCLUSIONS: Use of a two-dose HBV vaccine would increase the number of adults fully seroprotected at one year compared with the number expected with a three-dose vaccine. Notwithstanding its higher unit cost, mean expected cost per person seroprotected is substantially lower for HEPLISAV-B than ENGERIX-B as a result of much higher levels of seroprotection.
引用
- Oster G, Bornheimer R, Ottino K, et al. Adult immunization against hepatitis B: Does the number of jabs matter? Vaccine. 2022. PMID: 35570079. doi:10.1016/j.vaccine.2022.04.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。